20 related articles for article (PubMed ID: 38748459)
1.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
2. Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
Bae S; Sa S; Park S; Cho BS; Kim HJ
Acta Haematol; 2024; 147(3):352-359. PubMed ID: 37751714
[TBL] [Abstract][Full Text] [Related]
3. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Ionescu F; David JC; Ravichandran A; Sallman DA; Sweet K; Komrokji RS; Chan O; Kuykendall A; Padron E; Faramand R; Bejanyan N; Khimani F; Elmariah H; Pidala J; Mishra A; Perez L; Nishihori T; Lancet JE
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):400-406. PubMed ID: 38429222
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
[TBL] [Abstract][Full Text] [Related]
6. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
[No Abstract] [Full Text] [Related]
7. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
Berton G; Sedaki B; Collomb E; Benachour S; Loschi M; Mohty B; Saillard C; Hicheri Y; Rouzaud C; Maisano V; Villetard F; Corda ED'; Charbonnier A; Rey J; Hospital MA; Ittel A; Abbou N; Fanciullino R; Dadone-Montaudié B; Vey N; Venton G; Cluzeau T; Alary AS; Garciaz S
Leuk Res; 2024 Jun; 141():107500. PubMed ID: 38636413
[TBL] [Abstract][Full Text] [Related]
8. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH; Su Y; Patel S; Ramage CL; Zhao J; Temby BR; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Biochem Pharmacol; 2024 Feb; 220():115981. PubMed ID: 38081370
[TBL] [Abstract][Full Text] [Related]
9. Advancements and Challenges in the Treatment of AML.
Abaza Y; McMahon C; Garcia JS
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e438662. PubMed ID: 38662975
[TBL] [Abstract][Full Text] [Related]
10. Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes.
Zhang S; Lou S; Bian W; Liu J; Wang R; Wang Y; Zhao Y; Zou X; Jin D; Liang Y; Sun J; Liu L
Biochem Biophys Res Commun; 2024 Jul; 719():150117. PubMed ID: 38761635
[TBL] [Abstract][Full Text] [Related]
11. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
Marinoff AE; Aaronson K; Agrawal AK; Braun BS; Golden C; Huang BJ; Michlitsch J; Southworth E; Thrall A; Vo KT; Stieglitz E
Pediatr Blood Cancer; 2023 Jun; 70(6):e30335. PubMed ID: 37036306
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Madero-Marroquin R; Dworkin E; Weiner H; Saygin C; Nawas MT; Drazer MW; DuVall AS; Kosuri S; Thirman MJ; Odenike O; Stock W; Larson RA; Patel AA
Leuk Lymphoma; 2024 Jun; 65(6):864-867. PubMed ID: 38441062
[No Abstract] [Full Text] [Related]
14. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E; Cohen I; Amitai I; Ram R; Frisch A; Nachmias B; Canaani J; Moshe Y; Krayem B; Aumann S; Henig I; Vainstein V; Shargian L; Ganzel C; Yeshurun M; Levi I; Raanani P; Akria L; Ofran Y; Shimony S; Wolach O
Br J Haematol; 2024 May; ():. PubMed ID: 38782575
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM; Prebet T; Itzykson R; Ramos F; Al-Ali H; Shammo J; Pinto R; Maurillo L; Wetzel J; Musto P; Van De Loosdrecht AA; Costa MJ; Esteves S; Burgstaller S; Stauder R; Autzinger EM; Lang A; Krippl P; Geissler D; Falantes JF; Pedro C; Bargay J; Deben G; Garrido A; Bonanad S; Diez-Campelo M; Thepot S; Ades L; Sperr WR; Valent P; Fenaux P; Sekeres MA; Greil R; Pleyer L
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420120
[TBL] [Abstract][Full Text] [Related]
16. Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma.
Jian X; Cha J; Lin Z; Xie S; Huang Y; Lin Y; Zhao H; Xu B; Luo Y
Discov Oncol; 2024 Jun; 15(1):210. PubMed ID: 38834922
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
